Navigation Links
Intra-Cellular Therapies Announces Closing of $60 Million Private Placement and Completion of Reverse Merger
Date:9/3/2013

schizophrenia and other CNS disorders.  Recently, ITI announced the successful completion of a Phase I single rising dose study of the lead molecule in the ITI/Takeda collaboration, ITI-214.  ITI has additional programs in the areas of Parkinson's disease, Alzheimer's disease, depression, and cardiovascular disease.

FORWARD LOOKING STATEMENTS

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of ITI's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, plans to seek to have the Company's common stock quoted in the OTC Markets, and future research and clinical trials. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, ITI may not obtain approval to market its product candidates, uncertainties associated with regulatory filings and applications, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further li
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
2. Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
3. The Dyslipidemia Market Will Grow to $31 Billion in 2022, Driven by the Launch of Novel Therapies
4. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
5. CSL Biotherapies initiates shipments of its seasonal influenza vaccine to U.S. customers
6. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
7. The Launch of Three New Parkinsons Disease Therapies Through 2015 Will Help Offset Market Losses Resulting from the Growing Impact of Generics
8. Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share
9. NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
10. In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
11. Tafinlar in Combination with Mekinist and Nivolumab Have Considerable Efficacy and Tolerability Advantages Over Currently Used Therapies for the Treatment of Unresectable Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces that ... to the announced tender offer for all of the outstanding shares ... of the waiver, the transaction is no longer conditional on OFT ... 24, 2014 following the currently scheduled expiration time, subject to the ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... , LACHEN, Switzerland , Jan. ... of plasma products in the world, today announced that it has received ... Food and Drug Administration (FDA). The approval was granted for the ... bleeding episodes in patients with severe von Willebrand disease (VWD) as well ...
... , SUNNYVALE, Calif. , Jan. 13 ... of radiosurgery, today announced that it will report results for its fiscal second ... 4, 2010 after the market closes. , A conference call to review ... EST and will be hosted by Euan S. Thomson , Ph.D., ...
Cached Medicine Technology:Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 5Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease 6Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2010 2Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2010 3
(Date:7/9/2014)... poor printing on prescription labels handed out by ... errors in taking medication, according to new research ... National Institute for the Blind)., The study, published ... found that labels on prescription medications dispensed by ... for legibility. , By simply following recommended guidelines ...
(Date:7/9/2014)... , , , , , ... , , , ... weapon was an SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , ... , , , , ... , , , , ...
(Date:7/9/2014)... allergic diseases has risen dramatically in Western societies. One ... to microorganisms and have fewer infections than previous generations, ... study by researchers at Sahlgrenska Academy, University of Gothenburg, ... maturation of the immune system in relation to allergic ... of the Vstra Gtaland Region, half of them on ...
(Date:7/8/2014)... Older kidney donors enjoy similar longevity and cardiovascular health ... study published in the American Journal of Transplantation ... individuals considering donation and the transplant professionals caring for ... donation by individuals aged 55 years and older has ... kidney disease, and heart disease, the removal of a ...
(Date:7/8/2014)... Defense Advanced Research Projects Agency (DARPA) awarded Lawrence ... to develop an implantable neural device with the ... brain to help restore memory, DARPA officials announced ... understanding that memory is a process in which ... information, store it and retrieve it. Certain types ...
Breaking Medicine News(10 mins):Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:Study finds kidney donation safe for healthy older adults 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3
... New research shows that individual exacerbations in chronic ... of repeat exacerbations, even after five days of ... where each exacerbation can drive the progression of ... are not random has important implication for the ...
... JEFFREY KRONSON, M.D. CHALLENGES NOTION THAT CUTTING IS THE ... River,s "Men Are Stupid And They Like Big Boobs" ... effort to coerce women into plastic surgery to be ... remains convinced that younger women and men are getting ...
... meet weight-linked healthcare needs of 6.2 million kids , , ... called a "landmark agreement," former President Bill Clinton and ... a national initiative on childhood obesity, aimed at getting ... visits to both primary care physicians and dietitians. , ...
... KALAMAZOO, Mich., Feb. 19 Esphera3 International (E3I) ... on the principles of "Patient Focused Care." Currently ... encompasses all aspects of a partnered care health ... resource management and financial operations of healthcare.E3I and ...
... 19 Leading Veterans organizations this week ... early lung cancer detection research at the ... strongly supported by the Lung Cancer Alliance ... organizations issue the "Independent Budget" request to ...
... There are approximately 7.1 million injury-related emergency department (ED) ... States annually, according to the Centers for Disease Control ... universities, including the University of Missouri, found that young ... to have been reported to Child Protective Services (CPS) ...
Cached Medicine News:Health News:Exacerbations in COPD: One thing leads to another 2Health News:Exacerbations in COPD: One thing leads to another 3Health News:Joan River's New Plastic Surgery Promotion Book is Out of Sync With What Women Really Need to Hear About Going Under The Knife! 2Health News:Bill Clinton, Health Groups to Tackle Childhood Obesity 2Health News:Esphera3 International Founded on 'Patient Focused Care' 2Health News:Veterans Organizations Call For Early Lung Cancer Detection Research 2Health News:Researchers recommend increased physician awareness to reduce injuries and neglect in children 2
Designed for the effective positioning of patients during spinal surgery, the frame gives the surgeon a remarkably simple and versatile surgical tool....
High temperature loop tip cautery....
Low temp, micro fine tip, patented Aaron RAM cauteries....
6 mm, 45 degree upwards, detachable....
Medicine Products: